Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients – a Bayesian network meta-analysis

Taieb, V.; Ikeoka, Hidetoshi; Wojciechowski, Piotr; Jabłońska, Katarzyna; Aballéa, Samuel; Hill, Mark; Hirotsu, Nobuo

doi:10.1080/03007995.2020.1839400

Cited by 25 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiviral treatment within 48 hours of illness onset can shorten the duration of fever and other symptoms [6,7]. Moreover, antivirals can reduce viral shedding, suggesting that they may lead to suppression of transmission [8].…”

Section: Introductionmentioning

confidence: 99%

Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis

Hosogaya

Takazono

Yokomasu

et al. 2021

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis

Hosogaya

Takazono

Yokomasu

et al. 2021

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The median time to alleviation of influenza symptoms for baloxavir was 77.0 h (95% CI: 68.4-88.3 h), as observed in the clinical trial 8 . The time to alleviation of symptoms for laninamivir was estimated at 98.6 h (95% CI: 65.2-148.8 h) in the NMA 25 .…”

Section: Utilitiesmentioning

confidence: 98%

“…Demographic characteristics from the phase III clinical trial were not used to avoid possible bias due to the low sample size. 25 : probability of DRAEs: OR ¼ 1.80 (95% CrI: 1.05-3.12); probability of bronchitis: OR ¼ 1.01 (95% CrI: 0.17-5.90); difference in time to alleviation of symptoms: 21.62 h (95% CrI: -11.85-71.75). b Due to the lack of data for the probability of pneumonia and otitis for baloxavir (no patients experience these complications in the clinical trial), the upper bound was set equal to the upper bound of the corresponding parameter for laninamivir.…”

Section: Population Characteristicsmentioning

confidence: 99%

“…The phase III clinical trial provided the probability of DRAEs for baloxavir 9 . An odds ratio obtained from the network meta-analysis (NMA) was used to calculate the probability of DRAEs for laninamivir 25 .…”

Section: Drug-related Adverse Eventsmentioning

confidence: 99%

“…The probabilities of all complications for baloxavir were based on the data from the baloxavir arm of the trial. The probability of bronchitis for laninamivir was obtained from an NMA 25 . The probabilities of the other complications for laninamivir (pneumonia, sinusitis and otitis media) were based on pooled data from the oseltamivir and baloxavir arms 8 , as no data for laninamivir were found.…”

Section: Influenza-related Complicationsmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan

Dronova¹,

Ikeoka

Itsumura

et al. 2021

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

Objective: Baloxavir marboxil (baloxavir) is a single-dose antiviral which was previously found to be a cost-effective alternative to laninamivir in otherwise healthy adults in Japan. This study aimed at investigating the cost-effectiveness of baloxavir versus laninamivir in patients with influenza at high risk for complications. Methods: A decision tree was utilized to estimate costs and health gains associated with the use of antivirals. A lifetime horizon was applied to capture the long-term impact of influenza complications, and other events with associated costs and health outcomes were accounted for one influenza season. The study population was stratified into three categories: adolescents and non-elderly adults with high-risk conditions (HRC), elderly without other HRC, and elderly with other HRC. The cost-effectiveness was assessed from a public healthcare payer's perspective. The duration of influenza symptoms, probabilities of complications and probabilities of adverse events were obtained from a clinical trial and network meta-analysis. The costs of influenza and adverse events management were derived from the JammNet claims database. Utility values were informed by the clinical trial data and literature. Sensitivity analyses were also performed. Results: The baloxavir strategy was associated with higher costs (þ¥144) and higher quality-adjusted life-years (QALYs) in adults with HRC, elderly without HRC and elderly with HRC (þ0.00078, þ0.00183 and þ0.00350 respectively). The overall incremental cost/QALY for baloxavir versus laninamivir was ¥68,855, which was below the willingness-to-pay threshold of ¥5 million/QALY gained. Key drivers of the model results were the probability of pneumonia and bronchitis. The probability of baloxavir being cost-effective was 72%. Conclusions: This study suggests that influenza treatment with baloxavir is cost-effective compared with laninamivir in the adult high-risk population in Japan.

show abstract

Efficacy and safety of single‐dose antiviral drugs for influenza treatment: A systematic review and network meta‐analysis

Zhao

Huang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

To conduct network meta-analysis (NMA) of clinical efficacy and safety of singledose antiviral drugs, grouped by dosage, in treatment of influenza. Systematic retrievals were conducted in databases, including Pubmed, Embase, Web of Science, the Cochrane Register of Clinical Trials and from the website ClinicalTrials.gov, for clinical trials recorded between the interception of the databases and March 31, 2021. Randomized controlled trials (RCTs) of influenza treatment in which singledose antiviral drugs were administered were selected according to preset inclusion and exclusion criteria by two researchers who screened the literature independently from each other. The quality of the included studies was assessed using the Cochrane bias risk assessment tool. Software such as Stata 16.0 and Review Manager 5.3 was adopted for statistical analysis. Pairwise meta-analysis and NMA were carried out under the random-effects model. For both binary and continuous variables, odds ratio (OR), mean difference (MD) and their 95% confidence intervals (CI) were used to rank treatment efficiencies and analyze the differences. A total of 12 RCTs involving 7296 participants were included in the analysis. According to the

show abstract

Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients – a Bayesian network meta-analysis

Abstract: Hirotsu (2020): Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients-a Bayesian network meta-analysis, Current Medical Research and Opinion,

Cited by 25 publications

References 16 publications

Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis

Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis

Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan

Efficacy and safety of single‐dose antiviral drugs for influenza treatment: A systematic review and network meta‐analysis

Contact Info

Product

Resources

About